94 related articles for article (PubMed ID: 28464601)
1. Discrimination of CD44 and Oct3/4 Expression in Pancreatic Adenocarcinoma from Benign Pancreatic Ducts in Small Biopsy Specimens.
Lee CC; Kuo WH; Lin CK; Gao HW; Tsai WC
Chin J Physiol; 2017 Apr; 60(2):81-88. PubMed ID: 28464601
[TBL] [Abstract][Full Text] [Related]
2. ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma.
Grützmann R; Lüttges J; Sipos B; Ammerpohl O; Dobrowolski F; Alldinger I; Kersting S; Ockert D; Koch R; Kalthoff H; Schackert HK; Saeger HD; Klöppel G; Pilarsky C
Br J Cancer; 2004 Mar; 90(5):1053-8. PubMed ID: 14997207
[TBL] [Abstract][Full Text] [Related]
3. Characterization of OCT3/4, Nestin, NANOG, CD44 and CD24 as stem cell markers in canine prostate cancer.
Costa CD; Justo AA; Kobayashi PE; Story MM; Palmieri C; Laufer Amorim R; Fonseca-Alves CE
Int J Biochem Cell Biol; 2019 Mar; 108():21-28. PubMed ID: 30633985
[TBL] [Abstract][Full Text] [Related]
4. Annexin A10 is a candidate marker associated with the progression of pancreatic precursor lesions to adenocarcinoma.
Zhu J; Wu J; Pei X; Tan Z; Shi J; Lubman DM
PLoS One; 2017; 12(4):e0175039. PubMed ID: 28369074
[TBL] [Abstract][Full Text] [Related]
5. Expression of cancer stem cell markers in pancreatic intraepithelial neoplasias and pancreatic ductal adenocarcinomas.
Kure S; Matsuda Y; Hagio M; Ueda J; Naito Z; Ishiwata T
Int J Oncol; 2012 Oct; 41(4):1314-24. PubMed ID: 22824809
[TBL] [Abstract][Full Text] [Related]
6. Inflammation-related DNA damage and expression of CD133 and Oct3/4 in cholangiocarcinoma patients with poor prognosis.
Thanan R; Pairojkul C; Pinlaor S; Khuntikeo N; Wongkham C; Sripa B; Ma N; Vaeteewoottacharn K; Furukawa A; Kobayashi H; Hiraku Y; Oikawa S; Kawanishi S; Yongvanit P; Murata M
Free Radic Biol Med; 2013 Dec; 65():1464-1472. PubMed ID: 23917144
[TBL] [Abstract][Full Text] [Related]
7. The detection of tumor location and lymph node metastasis by aberrant NXPH1 and NXPH2 expressions in pancreatic ductal adenocarcinomas.
Jin JS; Tsai WC
Chin J Physiol; 2016 Dec; 59(6):348-354. PubMed ID: 27817196
[TBL] [Abstract][Full Text] [Related]
8. Cd44: a marker of squamous differentiation in adenosquamous neoplasms.
Ylagan LR; Scholes J; Demopoulos R
Arch Pathol Lab Med; 2000 Feb; 124(2):212-5. PubMed ID: 10656728
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of CD90 (Thy-1) in pancreatic adenocarcinoma present in the tumor microenvironment.
Zhu J; Thakolwiboon S; Liu X; Zhang M; Lubman DM
PLoS One; 2014; 9(12):e115507. PubMed ID: 25536077
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical Antibody Panel for the Differential Diagnosis of Pancreatic Ductal Carcinoma From Gastrointestinal Contamination and Benign Pancreatic Duct Epithelium in Endoscopic Ultrasound-Guided Fine-Needle Aspiration.
Furuhata A; Minamiguchi S; Shirahase H; Kodama Y; Adachi S; Sakurai T; Haga H
Pancreas; 2017 Apr; 46(4):531-538. PubMed ID: 28099249
[TBL] [Abstract][Full Text] [Related]
11. CD44 in normal human pancreas and pancreatic carcinoma cell lines.
Ringel J; Jesnowski R; Schmidt C; Ringel J; Köhler HJ; Rychly J; Batra SK; Löhr M
Teratog Carcinog Mutagen; 2001; 21(1):97-106. PubMed ID: 11135324
[TBL] [Abstract][Full Text] [Related]
12. CD24 and S100A4 expression in resectable pancreatic cancers with earlier disease recurrence and poor survival.
Lee SH; Kim H; Hwang JH; Shin E; Lee HS; Hwang DW; Cho JY; Yoon YS; Han HS; Cha BH
Pancreas; 2014 Apr; 43(3):380-8. PubMed ID: 24622067
[TBL] [Abstract][Full Text] [Related]
13. Visualization of CD44 and CD133 in normal pancreas and pancreatic ductal adenocarcinomas: non-overlapping membrane expression in cell populations positive for both markers.
Immervoll H; Hoem D; Steffensen OJ; Miletic H; Molven A
J Histochem Cytochem; 2011 Apr; 59(4):441-55. PubMed ID: 21411814
[TBL] [Abstract][Full Text] [Related]
14. Expression analysis of putative stem cell markers in human benign and malignant prostate.
Ugolkov AV; Eisengart LJ; Luan C; Yang XJ
Prostate; 2011 Jan; 71(1):18-25. PubMed ID: 20583131
[TBL] [Abstract][Full Text] [Related]
15. Histological and prognostic importance of CD44(+) /CD24(+) /EpCAM(+) expression in clinical pancreatic cancer.
Ohara Y; Oda T; Sugano M; Hashimoto S; Enomoto T; Yamada K; Akashi Y; Miyamoto R; Kobayashi A; Fukunaga K; Morishita Y; Ohkohchi N
Cancer Sci; 2013 Aug; 104(8):1127-34. PubMed ID: 23679813
[TBL] [Abstract][Full Text] [Related]
16. Variant of ductal adenocarcinoma of pancreas.
Suda K; Nobukawa B; Mogaki M; Fujii H; Matsumoto Y
Pancreas; 1999 Oct; 19(3):318-20. PubMed ID: 10505765
[No Abstract] [Full Text] [Related]
17. Pancreatic cancer stem cells: their role in pancreatic cancer patient outcomes and what is future?
Habib M; Saif MW
JOP; 2013 Jul; 14(4):401-4. PubMed ID: 23846937
[TBL] [Abstract][Full Text] [Related]
18. Expression and Clinical Significance of Cancer Stem Cell Markers CD24, CD44, and CD133 in Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis.
Durko L; Wlodarski W; Stasikowska-Kanicka O; Wagrowska-Danilewicz M; Danilewicz M; Hogendorf P; Strzelczyk J; Malecka-Panas E
Dis Markers; 2017; 2017():3276806. PubMed ID: 28659655
[TBL] [Abstract][Full Text] [Related]
19. Cancer-initiating cells in human pancreatic cancer organoids are maintained by interactions with endothelial cells.
Choi JI; Jang SI; Hong J; Kim CH; Kwon SS; Park JS; Lim JB
Cancer Lett; 2021 Feb; 498():42-53. PubMed ID: 33188841
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of stem cell-related marker expression and its correlation with histologic subtypes in lung adenocarcinoma.
Park E; Park SY; Sun PL; Jin Y; Kim JE; Jheon S; Kim K; Lee CT; Kim H; Chung JH
Oncotarget; 2016 Jul; 7(27):42502-42512. PubMed ID: 27285762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
